You are currently browsing the archives for 30 November 2017.
Displaying 1 entry.

The principal investigator for the trial.

The primary endpoint would be the modify in the level of alanine aminotransferase , a liver enzyme that’s produced in higher quantities when the liver is certainly inflamed, at the end of the procedure period weighed against baseline. Mitochondrial protective agents and mitochondria-directed antioxidants signify a unique direction for the development of drug candidates that can change the pathogenesis of persistent Hepatitis C, said Dr. Ken Taylor, CEO of Antipodean. MitoQ is certainly a promising compound in this and other areas. We think that MitoQ could be used to prevent or lower liver fibrosis and swelling progression, even in the absence of sustained virologic response.